MyFinsight
Home
Blog
About
Proceeds from sale of
equipment
$18K
Net cash used in
investing activities
$18K
(113.14%↑ Y/Y)
Net decrease in
cash, cash...
-$19,892K
(50.96%↑ Y/Y)
Canceled cashflow
$18K
Share-based compensation
expense
$4,231K
(-67.10%↓ Y/Y)
Right-of-use assets
-$665K
(64.63%↑ Y/Y)
Depreciation and
amortization
$643K
(-59.30%↓ Y/Y)
Accounts payable
$321K
(-90.64%↓ Y/Y)
Prepaid expense and
other assets
-$299K
(92.79%↑ Y/Y)
Accrued liabilities
$173K
(101.21%↑ Y/Y)
Loss on disposal of
property and equipment
-$72K
Foreign currency
transaction loss
-$7K
(95.30%↑ Y/Y)
Net cash used in
operating activities
-$19,910K
(51.31%↑ Y/Y)
Canceled cashflow
$6,411K
Revenue
$2,959K
(-94.87%↓ Y/Y)
Other
-$1,760K
(66.06%↑ Y/Y)
Net loss
-$23,785K
(-2.27%↓ Y/Y)
Canceled cashflow
$4,719K
Deferred revenue
-$1,334K
(88.96%↑ Y/Y)
Lease liabilities
-$714K
(65.42%↑ Y/Y)
Accounts receivable
$470K
(-96.45%↓ Y/Y)
Gain on sale of
equipment
$18K
Total research and
development
$17,515K
General and
administrative
$10,989K
(-49.25%↓ Y/Y)
Back
Back
Cash Flow
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)
source: myfinsight.com